this page is secure

A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia‐chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria

Buy Article:

Authors: Murai, Kazunori; Akagi, Tomoaki; Shimosegawa, Kenji; Sugawara, Tomohiro; Ishizawa, Kenichi; Ito, Shigeki; Murai, Keiko; Motegi, Mutsuhito; Yokoyama, Hisayuki; Noji, Hideyoshi; Tajima, Katsushi; Kimura, Jun; Chou, Takaaki; Ogawa, Kazuei; Harigae, Hideo; Kubo, Kohmei; Oba, Koji; Sakamoto, Junichi; Ishida, Yoji

Source: European Journal of Haematology, Volume 95, Number 6, 1 December 2015, pp. 558-565(8)

Publisher: Wiley-Blackwell

DOI: https://doi.org/10.1111/ejh.12536

We conducted a phase II study to evaluate the efficacy and safety of dasatinib in Japanese patients with imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia (CML).

No References

No Citations

No Supplementary Data

No Article Media

No Metrics

Keywords: European LeukemiaNet 2013 recommendations; chronic myeloid leukemia; dasatinib; major molecular response; molecular response ≧4.5 log reduction

Document Type: Research Article

Publication date: December 1, 2015

Access Key
Free content
Partial Free content
New content
Open access content
Partial Open access content
Subscribed content
Partial Subscribed content
Free trial content

A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia‐chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria

Buy Article:

Sign-in

Tools

Share Content

Cookie Policy